about
The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.Practical considerations for the clinical use of buprenorphine.Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.Buprenorphine for opioid dependenceHealth-related quality of life changes associated with buprenorphine treatment for opioid dependence.Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network.Strategies for preventing heroin overdose.Hepatitis infection in the treatment of opioid dependence and abuse.Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.Participant characteristics and buprenorphine dose.The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level AnalysisStates' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.Financial factors and the implementation of medications for treating opioid use disorders.To Be Free and Normal: Addiction, Governance, and the Therapeutics of BuprenorphineAcute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence.
P2860
Q30490602-AAF4CAAB-6534-4967-94C7-660A757BF9ACQ33774853-A0B5C45F-9624-4502-AFAF-764E71E5A038Q34081656-B5F7D4B0-8C5D-4645-8C67-4F295D5DD418Q34119459-15AC7D7F-8863-45B9-A1CA-A40343377EB2Q34129263-86717303-836F-41B0-B726-4D4B043C742EQ34615753-1B48FFD2-CC53-42E9-8C75-3A3B889AB9E1Q35065975-48D59D05-CEEF-43C9-8558-CDF83D80FAA3Q35069474-3F5B3D4D-E8CB-46BF-85A1-39D4A9EE654BQ35389163-12C36E17-E7E6-4F29-B545-8B9A45A82E76Q35577449-F3C52E1F-DD91-4637-9B1F-761C6972A712Q35738688-97D63F57-0CB4-4D88-81BF-E02D27CC2B3FQ35828982-2FE21EB7-2609-49F7-A8BD-16047B9B9027Q36328320-C6B01B62-6A57-4AB0-927F-B814330B8B50Q36381418-2108DAA6-0914-42E7-BECC-5DCFEC38167FQ36399916-4817C8B7-22E4-46CA-9867-81A74AD18E00Q38104462-56D15471-B57F-4F7B-BBEA-8A6A348A20CEQ42649099-432EA266-8AAA-4CCF-8027-E3A344BAFD7D
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Buprenorphine: blending practice and research.
@ast
Buprenorphine: blending practice and research.
@en
Buprenorphine: blending practice and research.
@nl
type
label
Buprenorphine: blending practice and research.
@ast
Buprenorphine: blending practice and research.
@en
Buprenorphine: blending practice and research.
@nl
prefLabel
Buprenorphine: blending practice and research.
@ast
Buprenorphine: blending practice and research.
@en
Buprenorphine: blending practice and research.
@nl
P1476
Buprenorphine: blending practice and research.
@en
P2093
David Smith
Walter Ling
P356
10.1016/S0740-5472(02)00257-X
P577
2002-09-01T00:00:00Z